Clinical Trial Update: Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase [Phase 3]

View source ↗

Summary

Safety data from a 6-month open-label extension of buprenorphine transdermal system (BTDS) in adults with osteoarthritis pain of the hip or knee (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• BUPRENORPHINE TRANSDERMAL SYSTEM (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Osteoarthritis | Phase 3 | Status: COMPLETED | Results posted: 2010-09-21